Gain Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 26, 2024

GANX$1.09+5.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets


· December 31, · December 31,
· · · 2023 · · 2022
Assets · ·
Current assets: · ·
Cash and cash equivalents	$11,794,949	$7,311,611
Marketable securities - current	4,999,704	12,826,954
Tax credits	242,577	103,877
Prepaid expenses and other current assets	741,638	848,854
Total current assets	$17,778,868	$21,091,296

Non-current assets:
Marketable securities - non current	$—	$1,941,488
Property and equipment, net	125,962	144,379
Internal-use software	193,375	213,967
Operating lease - right of use assets	459,215	659,933
Restricted cash	34,021	30,818
Long-term deposits and other non-current assets	17,890	17,506
Total non-current assets	830,463	3,008,091
Total assets	$18,609,331	$24,099,387

Liabilities and stockholder's equity
Current liabilities:
Accounts payable	$1,318,965	$1,626,100
Operating lease liability - current	229,693	229,080
Other current liabilities	2,160,366	2,106,756
Deferred income - current	1,122,138	55,180
Loans - current	118,797	108,135
Total current liabilities	$4,949,959	$4,125,251

Non-current liabilities:
Defined benefit pension plan	$307,454	$157,580
Operating lease liability - non-current	229,855	441,784
Deferred income - non-current	94,786	—
Loans - non-current	449,053	495,258
Total non-current liabilities	1,081,148	1,094,622
Total liabilities	$6,031,107	$5,219,873

Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of December 31, 2023 and 2022	$—	$—
Common stock, $0.0001 par value: 50,000,000 shares authorized; 16,206,680 shares issued and outstanding as of December 31, 2023 and 11,883,368 shares issued and outstanding as of December 31, 2022	1,621	1,189
Additional paid-in capital	73,113,079	57,358,895
Accumulated other comprehensive income	247,241	35,627
Accumulated deficit	(38,516,197)	(20,925,459)
Loss of the period	(22,267,520)	(17,590,738)
Total stockholders’ equity	12,578,224	18,879,514
Total liabilities and stockholders’ equity	$18,609,331	$24,099,387

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.